


Article

# Optimal inhaled oxygen and carbon dioxide concentrations for post-cardiac arrest cerebral reoxygenation and neurological recovery



Chih-Hung Wang,  
Wei-Tien Chang,  
Chien-Hua Huang,  
Min-Shan Tsai,  
Chan-Chi Wang,  
Shing-Hwa Liu,  
Wen-Jone Chen

shinghwaliu@ntu.edu.tw  
(S.-H.L.)  
wjchen1955@ntu.edu.tw  
(W.-J.C.)

Highlights

Post-arrest cerebral blood flow and tissue oxygenation are mainly regulated by CO<sub>2</sub>

Reducing inhaled O<sub>2</sub> could not effectively mitigate post-arrest cerebral injuries

Inhaled CO<sub>2</sub> reduced hyperoxic injuries, facilitating neurological recovery

Inhalation of 50% O<sub>2</sub> and 12% CO<sub>2</sub> was most neuroprotective

Wang et al., iScience 26, 108476  
December 15, 2023 © 2023 The Authors.  
<https://doi.org/10.1016/j.isci.2023.108476>



## Article

## Optimal inhaled oxygen and carbon dioxide concentrations for post-cardiac arrest cerebral reoxygenation and neurological recovery

Chih-Hung Wang,<sup>1,2</sup> Wei-Tien Chang,<sup>1,2</sup> Chien-Hua Huang,<sup>1,2</sup> Min-Shan Tsai,<sup>1,2</sup> Chan-Chi Wang,<sup>1,2</sup> Shing-Hwa Liu,<sup>3,4,5,7,\*</sup> and Wen-Jone Chen<sup>1,2,6,7,8,\*</sup>

## SUMMARY

**Prolonged cerebral hypoperfusion after the return of spontaneous circulation (ROSC) from cardiac arrest (CA) may lead to poor neurological recovery. In a 7-min asphyxia-induced CA rat model, four combinations of inhaled oxygen (iO<sub>2</sub>) and carbon dioxide (iCO<sub>2</sub>) were administered for 150 min post-ROSC and compared in a randomized animal trial. At the end of administration, the partial pressure of brain tissue oxygenation (PbtO<sub>2</sub>) monitored in the hippocampal CA1 region returned to the baseline for the 88% iO<sub>2</sub> [ $\Delta$ PbtO<sub>2</sub>, median:  $-0.39$  (interquartile range: 5.6) mmHg] and 50% iO<sub>2</sub> [ $\Delta$ pbtO<sub>2</sub>,  $-2.25$  (10.9) mmHg] groups; in contrast, PbtO<sub>2</sub> increased substantially in the 88% iO<sub>2</sub>+12% iCO<sub>2</sub> [ $\Delta$ pbtO<sub>2</sub>, 35.05 (16.0) mmHg] and 50% iO<sub>2</sub>+12% iCO<sub>2</sub> [ $\Delta$ pbtO<sub>2</sub>, 42.03 (31.7) mmHg] groups. Pairwise comparisons (post hoc Dunn's test) indicated the significant role of 12% iCO<sub>2</sub> in augmenting PbtO<sub>2</sub> during the intervention and improving neurological recovery at 24 h post-ROSC. Facilitating brain reoxygenation may improve post-CA neurological outcomes.**

## INTRODUCTION

Annually, out-of-hospital cardiac arrest (CA) occurs in approximately 44 individuals per 100,000 people worldwide.<sup>1</sup> Only 8% of patients subsequently recover their neurological function.<sup>2</sup> Brain injury was reported to account for 65% of deaths during post-CA intensive care.<sup>3</sup> Post-CA brain injury<sup>4,5</sup> is induced by a primary hypoxia-ischemia insult during CA and cardiopulmonary resuscitation (CPR), which is followed by secondary injuries after the return of spontaneous circulation (ROSC) caused by protracted cerebral hypoperfusion.<sup>6–8</sup>

The goal in treating CA is to restore cerebral oxygen delivery and tissue oxygenation as the brain is a highly energy-consuming organ<sup>9</sup> susceptible to hypoxic injuries.<sup>10</sup> Cerebral oxygen delivery is primarily determined by cerebral blood flow (CBF) and blood oxygen content. Several pathophysiologic factors<sup>4,5</sup> have been identified which may influence CBF after ROSC, including microcirculatory perturbation,<sup>11,12</sup> cerebral edema,<sup>13</sup> blood pressure,<sup>8</sup> and partial pressures of carbon dioxide (PaCO<sub>2</sub>).<sup>14</sup> On the other hand, the oxygen content is determined by the amount of oxygen transported in circulation, including oxygen bound to hemoglobin and oxygen dissolved in the plasma, mainly controlled by partial pressures of arterial oxygen (PaO<sub>2</sub>).<sup>15</sup> Several methods have been tested to recover CBF, including thrombolytics to improve cerebral microcirculation,<sup>16</sup> hypertonic saline to resolve cerebral edema,<sup>13</sup> and vasopressors to elevate blood pressure.<sup>8</sup> The success of these previous studies<sup>8,13,16</sup> suggested that recovering CBF and cerebral reoxygenation may help facilitate post-CA neurological recovery.

Among the pathophysiologic factors influencing cerebral oxygen delivery,<sup>4,5</sup> PaO<sub>2</sub> and PaCO<sub>2</sub> were recognized by the resuscitation guidelines from American Heart Association<sup>17</sup> and European Resuscitation Council<sup>18</sup> as the critical respiratory parameters which should be immediately managed after patients achieved ROSC. However, the optimal ranges of PaO<sub>2</sub> and PaCO<sub>2</sub> to recover cerebral oxygenation remain unknown.<sup>17,18</sup> Increasing concentration of oxygen inhalation to enhance the arterial oxygen content has been posited as a vital method to improve post-CA cerebral oxygen delivery.<sup>5</sup> Nonetheless, supranormal PaO<sub>2</sub> has been noted to decrease CBF,<sup>19</sup> leading to adverse effects.<sup>20</sup> On the other hand, cerebrovascular resistance has been noted to increase for at least 24 h in comatose survivors of CA.<sup>21</sup> PaCO<sub>2</sub> could modulate cerebrovascular resistance and CBF through its impact on vascular smooth muscle.<sup>22</sup> Notably, after hypoxia-ischemia brain injury, the reactivity of the vasculature to PaCO<sub>2</sub> remains preserved,<sup>23</sup> suggesting the possibility of carbon dioxide as a critical factor in determining cerebral oxygen delivery after ROSC.

<sup>1</sup>Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan

<sup>2</sup>Department of Emergency Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

<sup>3</sup>Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan

<sup>4</sup>Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan

<sup>5</sup>Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

<sup>6</sup>Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan


<sup>7</sup>These authors contributed equally

<sup>8</sup>Lead contact

\*Correspondence: shinghwaliu@ntu.edu.tw (S.-H.L.), wjchen1955@ntu.edu.tw (W.-J.C.)

<https://doi.org/10.1016/j.isci.2023.108476>





**Figure 1. Study procedures and measurements at baseline, asphyxia, cardiac arrest, cardiopulmonary resuscitation, and reperfusion**

ABG, arterial blood gas; CA, cardiac arrest; CBF, cerebral blood flow; CPR, cardiopulmonary resuscitation; ECG, electrocardiogram; EtCO<sub>2</sub>, partial pressure of end-tidal carbon dioxide; HR, heart rate; MAP, mean arterial pressure; ROSC, return of spontaneous circulation.

In this study, we hypothesized that improving brain tissue reoxygenation may facilitate post-CA neurological recovery in an asphyxia-induced CA rat model. We assumed that adjusting the concentrations of inhaled oxygen (iO<sub>2</sub>) and carbon dioxide (iCO<sub>2</sub>) may augment cerebral reoxygenation after ROSC because of the effects of PaO<sub>2</sub> and PaCO<sub>2</sub> on CBF and oxygen content. We aimed to compare the effects of different combinations of iO<sub>2</sub> and iCO<sub>2</sub> concentrations on CBF, brain tissue oxygenation, and neurological outcomes to identify the optimal use of iO<sub>2</sub> and iCO<sub>2</sub> in post-ROSC care.

## RESULTS

### Baseline characteristics and resuscitation variables indicate successful randomization

Following the experimental protocol (Figure 1), 140 rats were used for the experiments, 96 of which were randomized to the study groups (Figure S1). Seven animals died before intervention completion, possibly caused by post-CA myocardial dysfunction.<sup>5,24</sup> Table 1 shows the baseline characteristics and resuscitation variables among the groups. The CPR time is noted to be numerically shorter in the 50% iO<sub>2</sub>+12% iCO<sub>2</sub> (median: 88 s, interquartile range [IQR]:76.3s) group than the 50% iO<sub>2</sub> (135s, IQR:162s) group. Nonetheless, the scatterplot (Figure S2) demonstrates no significant statistical differences between the 50% iO<sub>2</sub>+12% iCO<sub>2</sub> and the 50% iO<sub>2</sub> groups.

### Arterial blood gas (ABG) analysis observes the hyperoxia and hypercapnia caused by iO<sub>2</sub> and iCO<sub>2</sub>

At 60 min post-ROSC, ABG analysis shows that PaO<sub>2</sub> was above and below 300 mmHg in the groups administered 88% iO<sub>2</sub> and 50% iO<sub>2</sub>, respectively (Table 1; Figure S3). For groups receiving 12% iCO<sub>2</sub>, the median PaCO<sub>2</sub> was approximately 146 mmHg. Interestingly, although not receiving 12% iCO<sub>2</sub>, the 88% iO<sub>2</sub> and 50% iO<sub>2</sub> groups demonstrate that the median PaCO<sub>2</sub> levels are 65.4 and 58.1 mmHg, respectively.

### 12% iCO<sub>2</sub> increases CBF and PbtO<sub>2</sub> regardless of the iO<sub>2</sub> concentrations

As shown in Figure 2, and Table 1, in the 88% iO<sub>2</sub> and 50% iO<sub>2</sub> groups, after the initial hyperemic state, CBF decreases to 52% (IQR: 13%) and 50% (IQR: 16%) of baseline at 150 min post-ROSC, respectively. In contrast, in the 88% iO<sub>2</sub>+12% iCO<sub>2</sub> and 50% iO<sub>2</sub>+12% iCO<sub>2</sub> groups, CBF at 150 min post-ROSC are 292% (IQR: 43%) and 311% (IQR: 102%) of baseline, respectively. Along with CBF, partial pressure of brain tissue oxygenation (PbtO<sub>2</sub>) increases and decreases in groups with and without 12% iCO<sub>2</sub> administration, respectively. At 150 min post-ROSC, the ΔPbtO<sub>2</sub>, defined as PbtO<sub>2</sub> at a particular time point minus the baseline, suggests that PbtO<sub>2</sub> almost returns to the baseline value for 88% iO<sub>2</sub> [−0.39 (5.6) mmHg] and 50% iO<sub>2</sub> [−2.25 (10.9) mmHg] groups; in contrast, the ΔPbtO<sub>2</sub> data suggests that PbtO<sub>2</sub> increases substantially from the baseline in the 88% iO<sub>2</sub>+12% iCO<sub>2</sub> [35.05 (16.0) mmHg] and 50% iO<sub>2</sub>+12% iCO<sub>2</sub> [42.03 (31.7) mmHg] groups. Pairwise comparisons indicate that the between-group differences in CBF, PbtO<sub>2</sub>, and ΔPbtO<sub>2</sub> are mainly caused by 12% iCO<sub>2</sub>. For end-tidal carbon dioxide (EtCO<sub>2</sub>), Figure S4 suggests that the ventilation status or the PaCO<sub>2</sub> level may become stable after 30 min post-ROSC. In contrast, after 30 min post-ROSC, the CBF and PbtO<sub>2</sub> continue to increase in the groups receiving 12% iCO<sub>2</sub> (Figure 2). As for hemodynamics, Figure S4 reveals that different combinations of iO<sub>2</sub> and iCO<sub>2</sub> did not influence blood pressure. Also, Figure S4 demonstrates no significant differences in body temperature, which was controlled closely around the target temperature.

### 12% iCO<sub>2</sub> improves neurological recovery without influencing survival

Figure 3 and Table 1 demonstrate no differences in survival among the groups. For rats surviving 24 h, neurological function score (NFS) is significantly higher in the groups administered 12% iCO<sub>2</sub> than in the groups without it. Figure 4 and Table 1 reveal that, compared with the groups without 12% iCO<sub>2</sub> administration, the groups receiving 12% iCO<sub>2</sub> have lower neuron-specific enolase (NSE) and malondialdehyde (MDA) concentrations, suggesting fewer neuronal and oxidative injuries in the latter groups. In contrast, there are no significant differences in cardiac troponin I, suggesting that 12% iCO<sub>2</sub> administration may not cause myocardial injuries.

**Table 1. Baseline characteristics, peri-resuscitation variables, and outcomes of randomized animals**


Variables	88% iO <sub>2</sub> (n = 24)	50% iO <sub>2</sub> (n = 24)	88% iO <sub>2</sub> + 12% iCO <sub>2</sub> (n = 24)	50% iO <sub>2</sub> + 12% iCO <sub>2</sub> (n = 24)	p value <sup>a</sup>
<b>Baseline characteristics and resuscitation variables</b>					
Body weight, (g)	465 (47.5)	475 (26.3)	465 (51.3)	478 (41.3)	0.76
Cardiac arrest time, (s)	198 (30.3)	201 (20.3)	209 (27.8)	203 (27.8)	0.43
CPR time, (s)	113 (72)	135 (162)	116 (90.3)	88 (76.3)	0.33
<b>ABG analysis at 60 min post-ROSC</b>					
pH	7.27 (0.04) (n = 20)	7.28 (0.07) (n = 24)	7.03 (0.07) (n = 22)	7.05 (0.05) (n = 23)	<0.001
PaCO <sub>2</sub> , mmHg	65.4 (5.2) (n = 20)	58.1 (6.6) (n = 24)	146.9 (11.0) (n = 22)	146.3 (13.0) (n = 23)	<0.001
PaO <sub>2</sub> , mmHg	356.8 (43.2) (n = 20)	174.4 (71.6) (n = 24)	430.2 (79.5) (n = 22)	209.3 (112.5) (n = 23)	<0.001
HCO <sub>3</sub> <sup>-</sup> , mEq/L	31.7 (1.6) (n = 20)	30.7 (5.5) (n = 24)	39.4 (3.0) (n = 22)	39.8 (7.8) (n = 23)	<0.001
Base excess, mEq/L	4.9 (1.3) (n = 20)	3.4 (4.5) (n = 24)	9.0 (3.9) (n = 22)	9.5 (6.2) (n = 23)	<0.001
Lactate, mg/dL	10.6 (4.9) (n = 20)	8.4 (8.7) (n = 24)	11.3 (3.4) (n = 22)	4.6 (5.3) (n = 23)	0.001
<b>Physiological parameters at 150 min post-ROSC</b>					
CBF level, % of baseline	0.52 (0.13) (n = 20)	0.50 (0.16) (n = 24)	2.92 (0.43) (n = 22)	3.11 (1.02) (n = 23)	<0.001
PbtO <sub>2</sub> , mmHg	12.87 (15.0) (n = 20)	8.33 (11.0) (n = 24)	35.05 (16.0) (n = 22)	42.03 (31.7) (n = 23)	<0.001
ΔPbtO <sub>2</sub> , mmHg	-0.39 (5.6) (n = 20)	-2.25 (10.9) (n = 24)	28.91 (23.2) (n = 22)	38.88 (35.7) (n = 23)	<0.001
EtCO <sub>2</sub> , mmHg	60.5 (4.0) (n = 20)	51.0 (5.0) (n = 24)	138.5 (5.0) (n = 22)	131 (4.0) (n = 23)	<0.001
MAP, mmHg	98.3 (25.0) (n = 20)	100.4 (25.8) (n = 24)	97.2 (25.5) (n = 22)	101.2 (24.4) (n = 23)	>0.99
Body temperature, °C	36.8 (0.1) (n = 20)	36.9 (0.2) (n = 24)	36.9 (0.2) (n = 22)	36.8 (0.3) (n = 23)	0.21
<b>ELISA and TBARS at 24 h post-ROSC</b>					
NSE level at 24 h, ng/ml	0.663 (0.336) (n = 20)	0.828 (0.453) (n = 21)	0.351 (0.119) (n = 21)	0.305 (0.103) (n = 22)	<0.001
S100β level, pg/ml	1.461 (0.284) (n = 20)	1.562 (0.297) (n = 21)	1.397 (0.123) (n = 21)	1.404 (0.082) (n = 22)	0.03
MDA level, μM	93.2 (50.0) (n = 20)	91.3 (19.3) (n = 21)	59.0 (59.8) (n = 21)	64.9 (48.3) (n = 22)	<0.001
Cardiac troponin I, ng/ml	72.1 (58.7) (n = 20)	90.5 (69.2) (n = 21)	42.6 (48.0) (n = 21)	39.7 (50.5) (n = 22)	0.002
<b>TUNEL assay and FJC staining at 24 h post-ROSC</b>					
Density of TUNEL-positive cells: CA1, count/mm <sup>2</sup>	361.5 (179.2) (n = 6)	415.6 (142.8) (n = 6)	69.8 (15.6) (n = 6)	61.5 (24.5) (n = 6)	<0.001
Density of TUNEL-positive cells: CA3, count/mm <sup>2</sup>	364.6 (79.7) (n = 6)	358.3 (108.9) (n = 6)	58.3 (21.9) (n = 6)	61.5 (29.2) (n = 6)	<0.001
Density of FJC-positive cells: CA1, count/mm <sup>2</sup>	43.8 (16.2) (n = 6)	38.5 (6.8) (n = 6)	25.0 (7.3) (n = 6)	20.8 (10.4) (n = 6)	0.004
Density of FJC-positive cells: CA3, count/mm <sup>2</sup>	29.2 (10.4) (n = 6)	34.4 (9.9) (n = 6)	25.0 (10.4) (n = 6)	18.8 (10.9) (n = 6)	0.05
<b>Outcomes at 24 h post-ROSC</b>					
Survival, n (%)	20 (83)	21 (88)	21 (88)	22 (92)	0.86 <sup>b</sup>
Neurological function score	8.0 (1.0) (n = 20)	7.0 (1.0) (n = 21)	10.0 (1.0) (n = 21)	10.0 (0.0) (n = 22)	<0.001

Data are expressed as the median (interquartile range) or count (proportion). ABG, arterial blood gas; CBF, cerebral blood flow; CPR, cardiopulmonary resuscitation; ΔPbtO<sub>2</sub>, delta of partial pressure of brain tissue oxygenation; ELISA, enzyme-linked immunosorbent assay; EtCO<sub>2</sub>, partial pressure of end-tidal carbon dioxide; FJC, Fluoro-Jade C; HCO<sub>3</sub><sup>-</sup>, sodium bicarbonate; iCO<sub>2</sub>, inhaled carbon dioxide; iO<sub>2</sub>, inhaled oxygen MAP, mean arterial pressure; MDA, malondialdehyde; NSE, neuron-specific enolase; PaCO<sub>2</sub>, arterial partial pressure of carbon dioxide; PaO<sub>2</sub>, arterial partial pressure of oxygen; ROSC, return of spontaneous circulation; TBARS, thiobarbituric acid reactive substance; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

<sup>a</sup>The comparison was performed using Kruskal-Wallis test. The results of *post hoc* pairwise comparisons are annotated in corresponding figures.

<sup>b</sup>This comparison was performed using chi-squared test.

Figure 5 indicates lower densities of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the hippocampal CA1 and CA3 regions of the groups receiving 12% iCO<sub>2</sub>, suggesting that apoptosis has been attenuated. In contrast, regarding neural degeneration, only the 50% iO<sub>2</sub>+12% iCO<sub>2</sub> group exhibits a significantly lower density of Fluoro-Jade C (FJC)-positive cells than the 88% iO<sub>2</sub> and 50% iO<sub>2</sub> groups in the hippocampal CA1 region. No significant differences are observed in caspase-3 activation or PARP cleavage (Figure S5).



**Figure 2. Brain oxygenation during invasive monitoring**

(A), (C), and (E) Trends of CBF and PbtO<sub>2</sub> after administration of different combinations of iO<sub>2</sub> and iCO<sub>2</sub>. (B), (D), and (F) Levels of CBF and PbtO<sub>2</sub> at the end of the intervention, 150 min post-ROSC. Black: 50% iO<sub>2</sub> group; pink: 88% iO<sub>2</sub> group; green: 50% iO<sub>2</sub> + 12% iCO<sub>2</sub> group; purple: 88% iO<sub>2</sub> + 12% iCO<sub>2</sub> group. The administration of 12% iCO<sub>2</sub> increased CBF and PbtO<sub>2</sub>. Data are presented as the median with an interquartile range or a boxplot. Pairwise comparisons of physiological parameters between experimental groups were performed by *post hoc* Dunn's test. CA, cardiac arrest; CBF, cerebral blood flow; ΔPbtO<sub>2</sub>, delta of partial pressure of brain tissue oxygenation; iCO<sub>2</sub>, inhaled carbon dioxide; iO<sub>2</sub>, inhaled oxygen; KW: Kruskal-Wallis; ROSC, return of spontaneous circulation.

### Sensitivity analysis suggests 50% iO<sub>2</sub>+12% iCO<sub>2</sub> might be the optimal combination

The sensitivity analysis reveals significant interactions between iO<sub>2</sub> and iCO<sub>2</sub> in NFS ( $p < 0.001$ ) (Figure S6). *Post hoc* analysis suggests that the 50% iO<sub>2</sub>+12% iCO<sub>2</sub> and 50% iO<sub>2</sub> groups demonstrate the highest and lowest NFS, respectively, among all combinations of iO<sub>2</sub> and iCO<sub>2</sub>.


## DISCUSSION

### Main findings

First, post-CA CBF and PbtO<sub>2</sub> were mainly modulated by 12% iCO<sub>2</sub> rather than iO<sub>2</sub>. Second, reducing the iO<sub>2</sub> concentration from 88 to 50% could not effectively mitigate post-ROSC cerebral injuries. In contrast, 12% iCO<sub>2</sub> reduced the severity of hyperoxic injuries and facilitated neurological recovery. Third, the improved neurological outcomes could be explained by fewer neuronal injuries, reduced oxidative injuries, attenuated apoptosis, and decreased neuronal degeneration associated with 12% iCO<sub>2</sub>. Finally, there was a significant interaction between iO<sub>2</sub> and iCO<sub>2</sub>, suggesting that 50% iO<sub>2</sub> and 12% iCO<sub>2</sub> might be the most neuroprotective combination among all groups.

### Determining iO<sub>2</sub> and iCO<sub>2</sub> concentrations and intervention duration

PaO<sub>2</sub> >300 mmHg and PaO<sub>2</sub> between 101 and 299 mmHg were categorized as severe and moderate hyperoxia, respectively.<sup>25</sup> In this study, both groups administered 88% iO<sub>2</sub> achieved median PaO<sub>2</sub> above 300 mmHg (Table 1). PaO<sub>2</sub> >300 mmHg was reported to be



**Figure 3. Survival curves and neurological outcomes at 24 h post-ROSC**

(A) Kaplan-Meier survival curves.

(B) Neurological function scores at 24 h post-ROSC. Black: 50% iO<sub>2</sub> group; pink: 88% iO<sub>2</sub> group; green: 50% iO<sub>2</sub> + 12% iCO<sub>2</sub> group; purple: 88% iO<sub>2</sub> + 12% iCO<sub>2</sub> group. The neurological function score is presented as a boxplot. Pairwise comparisons between experimental groups were performed using *post hoc* Dunn's test. There were no significant differences in survival among experimental groups. The neurological function score was higher in groups with 12% iCO<sub>2</sub> than in groups without it. iCO<sub>2</sub>, inhaled carbon dioxide; iO<sub>2</sub>, inhaled oxygen; KW, Kruskal-Wallis; ROSC, return of spontaneous circulation.

associated with increased post-CA mortality.<sup>26</sup> In contrast, the median PaO<sub>2</sub> of groups receiving 50% iO<sub>2</sub> was 174 and 209 mmHg (Table 1). Conflicting findings about the association of PaO<sub>2</sub> between 101 and 299 mmHg with poor post-CA outcomes have been reported.<sup>27–31</sup> A prospective observational study<sup>32</sup> indicated that the association of PaO<sub>2</sub> with poor neurological outcome began at ≥ 300 mmHg. Meanwhile, an animal study<sup>33</sup> demonstrated that 24 h survival was higher in a group receiving 50% iO<sub>2</sub> (survival: 5/8, 62.5%) than in those receiving 21% (survival: 1/7, 14.3%) or 100% iO<sub>2</sub> (survival: 4/8, 50%) in a ventricular fibrillation (VF)-induced CA rat model. Therefore, from clinical and experimental perspectives, it may be reasonable to hypothesize that, compared with 88% iO<sub>2</sub>, 50% iO<sub>2</sub> would improve neurological outcomes.


As for the selection of iCO<sub>2</sub> concentration, no relevant clinical studies could be used for reference. In a prospective observational study, Kilgannon et al.<sup>34</sup> indicated that a mean PaCO<sub>2</sub> of 68 mmHg was associated with the highest chances of good neurological outcome. In the CCC trial, Eastwood et al.<sup>35</sup> compared PaCO<sub>2</sub> of 50–55 mmHg versus 35–45 mmHg in post-ROSC patients, revealing a lower NSE level in the former. Our previous dose-response study<sup>14</sup> tested and compared the effects of 4%, 8%, and 12% iCO<sub>2</sub> on CBF and neuroprotection. The results revealed significant linear trends between increasing iCO<sub>2</sub> concentrations and neuroprotective effects. Therefore, we selected 12% iCO<sub>2</sub> to maximize the neuroprotective effects, ensuring the hyperoxia injuries could be counteracted. Interestingly, the median PaCO<sub>2</sub> in 88% and 55% iO<sub>2</sub> groups were 65.4 and 58.1 mmHg, respectively, already achieving the PaCO<sub>2</sub> levels considered neuroprotective.<sup>34,35</sup> In a randomized clinical trial, Bernard et al.<sup>36</sup> demonstrated that the median PaCO<sub>2</sub> levels measured approximately 1 h after ROSC was 57 mmHg for patients resuscitated from out-of-hospital CA. The PaCO<sub>2</sub> levels noted in the Bernard et al.<sup>36</sup> trial were quite similar to the PaCO<sub>2</sub> levels measured at 60 min post-ROSC and EtCO<sub>2</sub> levels at 150 min post-ROSC in the 88% iO<sub>2</sub> and 50% iO<sub>2</sub> groups (Table 1). During the immediate post-ROSC period, cerebral injuries-associated depressed consciousness may cause hypoventilation and elevated PaCO<sub>2</sub>.<sup>37</sup> Therefore, the PaCO<sub>2</sub> or EtCO<sub>2</sub> levels in the 88% iO<sub>2</sub> and 50% iO<sub>2</sub> groups may reflect the clinical scenarios. Furthermore, in our experiments, the pentobarbital administered during animal preparation may also induce respiratory depression and lead to elevated PaCO<sub>2</sub> and EtCO<sub>2</sub> levels. If lower iCO<sub>2</sub> concentrations had been used, the neuroprotective effects could have been insignificant because of the slight between-group differences in PaCO<sub>2</sub>.

In an asphyxia-induced CA rat model, Drabek et al.<sup>6</sup> noted that after the initial hyperemia phase peaking at post-ROSC 7 min, a significant hypoperfusion phase ensued since post-ROSC 20 min till 60 min. Using a VF-induced CA rat model, Gong et al.<sup>7</sup> observed a sustained decrease of cerebral cortex microcirculation for 8 h following ROSC. For out-of-hospital CA, clinical trials<sup>36,38</sup> demonstrated that the interval between ROSC and ABG examination was approximately 90–150 min. After 90–150 min, clinicians may adjust iO<sub>2</sub> concentrations according to ABG results or other monitoring facilities without sticking to a predetermined inhalation concentration. Therefore, the selecting intervention duration to be 150 min may be reasonable.

### Influence of different iO<sub>2</sub> or iCO<sub>2</sub> concentrations on brain reoxygenation

In the 88% iO<sub>2</sub> group (Figures 2A and 2B), after initial hyperemia, CBF levels continued to decrease, indicating the “no-reflow” phenomenon.<sup>39,40</sup> Breathing high-concentration O<sub>2</sub> could cause significant cerebral vasoconstriction.<sup>41</sup> Nonetheless, reducing the iO<sub>2</sub> concentration





**Figure 4. ELISA and TBARS assay at 24 h post-ROSC**

(A) NSE levels.

(B) S100β levels.


(C) MDA: levels.

(D) Cardiac troponin I levels. Black: 50% iO<sub>2</sub> group; pink: 88% iO<sub>2</sub> group; green: 50% iO<sub>2</sub> + 12% iCO<sub>2</sub> group; purple: 88% iO<sub>2</sub> + 12% iCO<sub>2</sub> group. The neuronal injuries were evaluated using the NSE and S100β plasma concentrations. Oxidative injury was assessed using the MDA level in the hippocampus. Data are presented as a boxplot. Pairwise comparisons between experimental groups were performed using *post hoc* Dunn's test.

ELISA, enzyme-linked immunosorbent assay; iCO<sub>2</sub>, inhaled carbon dioxide; iO<sub>2</sub>, inhaled oxygen; KW: Kruskal-Wallis; MDA, malondialdehyde; NSE, neuron-specific enolase; ROSC, return of spontaneous circulation; TBARS, thiobarbituric acid reactive substance.

from 88% to 50% did not avoid post-ROSC cerebral hypoperfusion. In contrast, 12% iCO<sub>2</sub> significantly enhanced CBF, even if PaO<sub>2</sub> fell into the range of severe or moderate hyperoxia.

Figures 2C–2F show that, in the 88% and 50% iO<sub>2</sub> groups, PbtO<sub>2</sub> decreased gradually from the initial hyperemia stage, along with the declining CBF. Although PaO<sub>2</sub> in the 88% iO<sub>2</sub> group was nearly twice that in the 50% iO<sub>2</sub> group (Table 1), there were no significant differences in PbtO<sub>2</sub> between these two groups because the increase in PaO<sub>2</sub> only contributed to a small proportion of oxygen dissolved and transported by the CBF. In contrast, local tissue oxygenation is substantially determined by the regional blood flow,<sup>15</sup> and PbtO<sub>2</sub> may therefore be elevated by augmented CBF. Administration of 12% iCO<sub>2</sub> increased PaCO<sub>2</sub>, causing dilation of cerebral arteries and arterioles and augmented CBF.<sup>42</sup> Despite various theories proposed for vasodilation induced by elevated PaCO<sub>2</sub>, the primary mechanism seems to be



**Figure 5. TUNEL assay and FJC staining at 24 h post-ROSC**

(A) TUNEL assay of the hippocampus.

(B and C): Quantitative analysis of TUNEL assay for CA1 and CA3 regions, respectively.

(D) FJC staining of the hippocampus.

(E and F) Quantitative analysis of FJC staining for CA1 and CA3 regions, respectively. Black: 50% iO<sub>2</sub> group; pink: 88% iO<sub>2</sub> group; green: 50% iO<sub>2</sub> + 12% iCO<sub>2</sub> group; purple: 88% iO<sub>2</sub> + 12% iCO<sub>2</sub> group. Neuronal degeneration was evaluated by FJC staining. The hippocampal TUNEL-positive or FJC-positive cell density was used to quantify the level of apoptosis or neuronal degeneration, respectively. The coronal brain sections were subjected to TUNEL (green), FJC (green), and DAPI (bluish-violet) staining. Fluorescence microscopy was used to image hippocampal CA1 and CA3 regions at 50× magnification. Red rectangles indicate CA1 and CA3 regions selected for quantification. The scale bar represents 1000 μm. Samples were randomly selected for TUNEL assay or FJC staining. Data are presented as a boxplot. Pairwise comparisons between experimental groups were performed using *post hoc* Dunn's test.

DAPI, 4',6-diamidino-2-phenylindole; FJC, Fluoro-Jade C; iCO<sub>2</sub>, inhaled carbon dioxide; iO<sub>2</sub>, inhaled oxygen; KW, Kruskal-Wallis; ROSC, return of spontaneous circulation; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

associated with the direct impact of extracellular hydrogen ions on the smooth muscle of blood vessels.<sup>43</sup> By augmenting CBF, 12% iCO<sub>2</sub> increased PbtO<sub>2</sub> more efficiently.

At 150 min post-ROSC, PbtO<sub>2</sub> was 8.33–12.87 mmHg and 35.05–42.03 mmHg in the groups without and with 12% iCO<sub>2</sub>, respectively (Table 1). Normal PbtO<sub>2</sub> was suggested to be 23–35 mmHg but can vary depending on many factors, including measurement depth, and may be lower in deeper brain regions,<sup>44,45</sup> such as the hippocampal CA1 region monitored in our study. Hence, we calculated ΔPbtO<sub>2</sub> to reduce the between-subject variability in absolute PbtO<sub>2</sub>.<sup>46</sup> Sekhon et al.<sup>47</sup> noted that patients resuscitated from CA with a non-cardiac cause experienced a protracted period of critical cerebral hypoxia after ROSC, even when PaO<sub>2</sub> was controlled between 80 and 100 mmHg. Cerebral hypoxia was defined by Sekhon et al.<sup>47</sup> as PbtO<sub>2</sub> below 20 mmHg according to studies of traumatic brain injuries,<sup>45,48</sup> since there were no such definitions for post-ROSC patients. In the 88% and 50% iO<sub>2</sub> groups, the ΔPbtO<sub>2</sub> data suggested that PbtO<sub>2</sub> at 150 min post-ROSC nearly returned to the baseline value (Table 1). If baseline PbtO<sub>2</sub> was considered normal, the PbtO<sub>2</sub> in the 88% and 50% iO<sub>2</sub> groups was above the normal PbtO<sub>2</sub> for most of the observation period, suggesting no post-ROSC brain hypoxia. In contrast, for the groups receiving 12% iCO<sub>2</sub>, PbtO<sub>2</sub> substantially increased at 150 min post-ROSC, achieving a plateau significantly higher than the baseline.

It is possible that, even if PbtO<sub>2</sub> in the 88% and 50% iO<sub>2</sub> groups was above the baseline, the brain tissue might still suffer from hypoxic injuries. As the CBF at 150 min post-ROSC was just above half of the baseline (Table 1), PbtO<sub>2</sub> may be maintained by increased oxygen extraction from CBF to brain tissue. Gong et al.<sup>7</sup> demonstrated that the oxygen extraction ratio increased significantly after ROSC. Moreover, Hifumi et al.<sup>49</sup> noted an association of elevated lactate-to-pyruvate ratio (i.e., increased anaerobic metabolism) in brain tissue with poor neurological outcomes after CA. Therefore, 12% iCO<sub>2</sub> may elevate PbtO<sub>2</sub> to a new homeostatic state, maintaining the balance between oxygen delivery and consumption.



### Clinical outcomes and pathological findings

There were no significant differences between the 88% and 50%  $iO_2$  groups in the NFS and pathological findings, regardless of  $iCO_2$  concentrations. Similarly, using an asphyxia-induced CA rat model, Lipinski et al.<sup>50</sup> indicated that 21%  $iO_2$  during 60 min post-ROSC did not improve the neurological deficit or the histological injury, compared with 100%  $iO_2$ . The differences in post-ROSC CBF patterns and severity of brain damage between VF- and asphyxia-induced CA<sup>5,51</sup> may explain why reducing post-ROSC  $iO_2$  concentration in our study did not demonstrate significant neuroprotective effects as in previous studies.<sup>52</sup>

In most clinical studies,  $PaO_2 > 300$  mmHg was associated with poor post-CA neurological recovery<sup>32</sup> or mortality.<sup>26</sup> Nevertheless, most of these studies were based on observations in intensive care units.<sup>26,29,32</sup> Our study suggested that the difference in adverse effects between 88% and 50%  $iO_2$  administered for a short interval during the early post-ROSC period may not be as significant as the difference between high and low  $PaO_2$  exposure during a later period for a prolonged duration. This result may be reassuring since, in clinical practice, patients may receive oxygen at a high concentration for 30 min to several hours during the early post-ROSC period<sup>32,36,38,53</sup> until they are transported to the hospital, where safe monitoring is possible. In the EXACT trial,<sup>36</sup> even if patients were targeted at  $SpO_2$  between 98 and 100%, approximately 16.1% of them still experienced hypoxia ( $SpO_2 < 90\%$ ) before admission to an intensive care unit, which was worrying since hypoxia may be more detrimental than hyperoxia.<sup>54</sup> In the early post-ROSC period, therapeutics other than adjusting  $iO_2$  concentration may be needed to mitigate the injuries caused by hyperoxia.

Currently, the clinical evidence regarding the effects of  $PaCO_2$  on post-ROSC neurological recovery is inconsistent.<sup>35,55,56</sup> Our results revealed that the  $iCO_2$  could improve neurological outcomes (Figure 3) even when  $PaO_2$  was above the physiological range and may potentially cause hyperoxic injuries. The administration of  $iCO_2$  was associated with reduced NSE and MDA levels<sup>57</sup> (Figure 4) and lower TUNEL-positive and FJC-positive cell densities (Figure 5). No significant differences in caspase-3 activation or PARP cleavage were detected between groups with and without  $iCO_2$  (Figure S5). As western blotting was performed using brain tissue harvested at 24 h post-CA, initial apoptotic phases may have been completed at this time. Administering  $iCO_2$  may potentially cause severe acidosis and unfavorable clinical outcomes.<sup>58</sup> Although no  $iCO_2$ -associated adverse effects were observed in the current study, examining the effects of lower  $iCO_2$  concentrations against hyperoxic injuries in future studies would be worthwhile.

Finally, clinical studies indicated potential interactions between  $PaO_2$  and  $PaCO_2$ , demonstrating that the combination of moderate hyperoxia and mild hypercapnia was associated with lower mortality<sup>59</sup> and better neurological outcomes<sup>27</sup> after CA. Similarly, our sensitivity analysis indicated an interaction between  $iO_2$  and  $iCO_2$ , and the *post hoc* analysis suggested that the NFS was highest for the 50%  $iO_2$ +12%  $iCO_2$  group. Therefore, 50%  $iO_2$  and 12%  $iCO_2$  might be the optimal combination for brain reoxygenation among all tested groups.

### Conclusions

Facilitating brain reoxygenation may improve post-CA neurological outcomes. Reducing  $iO_2$  concentration from 88 to 50% has little influence on post-ROSC CBF and  $PbtO_2$ . In contrast, regardless of  $iO_2$  concentration, administering 12%  $iCO_2$  could facilitate brain reoxygenation and neurological recovery.

### Limitations of the study

The first limitation of this study is that it was performed using healthy animals. The impact of underlying disease on the recovery of CBF or  $PbtO_2$  by  $iCO_2$  is unknown. Thus, further studies on disease models are needed to clarify this issue. Second, only male animals were employed in the current experiment. Estrogen has been suspected to influence post-CA outcomes.<sup>60</sup> Therefore, most CA experiments were performed in male animals.<sup>51,62</sup> The generalizability to female subjects warrants further investigation. Third, neither the cerebral tissue oxygen extraction ratio nor the lactate-to-pyruvate ratio was measured, which limited our understanding of the mechanism by which increased CBF and  $PbtO_2$  led to better neurological recovery. Fourth, the CPR time was numerically shorter in the 50%  $iO_2$ +12%  $iCO_2$  group than in the 50%  $iO_2$  group. Despite the absence of statistically significant between-group difference (Figure S2), it remained possible that the shorter CPR duration could partially explain the better outcomes in the 50%  $iO_2$ +12%  $iCO_2$  group.<sup>63</sup> However, in our study, the rats were randomized in a block size of four to avoid the problem that the rats resuscitated in a temporally later period were resuscitated by investigators with more mature skills after repeated experiments. The Kaplan-Meier curves (Figure 3A) also do not show significant between-group differences in survival. Therefore, the numerical differences in the CPR time may occur by chance rather than systematic bias. Fifth, we used  $iCO_2$  to achieve hypercapnia instead of hypoventilating the animals. This selection was made because the effects of  $iCO_2$  on physiological parameters, including CBF and  $PaCO_2$ , were predictable and consistent according to our previous study results.<sup>14</sup> Nonetheless, using  $iCO_2$  may not be readily feasible in clinical practice and needs more studies to support its use. Our results may be considered hypothesis generating. Further studies are warranted to examine if a less aggressive method, i.e., hypoventilation controlled by mechanical ventilators, could achieve similar outcomes.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability

- Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Animals
  - Surgical preparation
  - Asphyxia-induced CA and CPR
  - Outcome measures of survival and neurological recovery
- **METHOD DETAILS**
  - Enzyme-linked immunosorbent assay (ELISA)
  - Thiobarbituric acid reactive substance (TBARS) assay
  - TUNEL assay
  - FJC staining
  - WB analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **ADDITIONAL RESOURCES**

## SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.isci.2023.108476>.

## ACKNOWLEDGMENTS

We thank the staff of the 3rd Core Lab, Department of Medical Research, National Taiwan University Hospital for technical support. Author C-H.W. received a grant (111-S0032) from the National Taiwan University Hospital and a grant (111-2628-B-002 -032 -MY3) from the National Science and Technology Council, Taiwan. National Taiwan University Hospital and National Science and Technology Council had no involvement in designing the study, collecting, analyzing or interpreting the data, writing the manuscript, or deciding whether to submit the manuscript for publication.

## AUTHOR CONTRIBUTIONS

C-H.W.: Conceptualization, Methodology, Validation, Resources, Formal analysis, Investigation, Data curation, Writing – original draft, Project administration; W-T.C.: Validation, Resources, Writing – review and editing, Project administration; C-H.H.: Resources, Writing – review and editing; M-S.T.: Writing – review and editing; C-C.W.: Investigation, Project administration; S-H.L.: Conceptualization, Methodology, Validation, Resources, Formal analysis, Writing – review and editing, Supervision; W-J.C.: Conceptualization, Methodology, Validation, Resources, Formal analysis, Writing – review and editing, Supervision.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: June 29, 2023

Revised: August 17, 2023

Accepted: November 14, 2023

Published: November 16, 2023

## REFERENCES

1. Berdowski, J., Berg, R.A., Tijssen, J.G.P., and Koster, R.W. (2010). Global incidences of out-of-hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies. *Resuscitation* *81*, 1479–1487.
2. Virani, S.S., Alonso, A., Benjamin, E.J., Bittencourt, M.S., Callaway, C.W., Carson, A.P., Chamberlain, A.M., Chang, A.R., Cheng, S., Delling, F.N., et al. (2020). Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation* *141*, e139–e596.
3. Lemiale, V., Dumas, F., Mongardon, N., Giovanetti, O., Charpentier, J., Chiche, J.D., Carli, P., Mira, J.P., Nolan, J., and Cariou, A. (2013). Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort. *Intensive Care Med.* *39*, 1972–1980.
4. Sekhon, M.S., Ainslie, P.N., and Griesdale, D.E. (2017). Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a "two-hit" model. *Crit. Care* *21*, 90.
5. Neumar, R.W., Nolan, J.P., Adrie, C., Aibiki, M., Berg, R.A., Bottiger, B.W., Callaway, C., Clark, R.S., Geocadin, R.G., Jauch, E.C., et al. (2008). Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. *Circulation* *118*, 2452–2483.
6. Drabek, T., Foley, L.M., Janata, A., Stezoski, J., Hitchens, T.K., Manole, M.D., and Kochanek, P.M. (2014). Global and regional differences in cerebral blood flow after asphyxial versus ventricular fibrillation cardiac arrest in rats using ASL-MRI. *Resuscitation* *85*, 964–971.
7. Gong, P., Zhao, S., Wang, J., Yang, Z., Qian, J., Wu, X., Cahoon, J., and Tang, W. (2015). Mild hypothermia preserves cerebral cortex microcirculation after resuscitation in a rat model of cardiac arrest. *Resuscitation* *97*, 109–114.

8. Wang, C.H., Chang, W.T., Huang, C.H., Tsai, M.S., Liu, S.H., and Chen, W.J. (2020). Cerebral Blood Flow-Guided Manipulation of Arterial Blood Pressure Attenuates Hippocampal Apoptosis After Asphyxia-Induced Cardiac Arrest in Rats. *J. Am. Heart Assoc.* **9**, e016513.
9. Clarke, D.D., and Sokoloff, L. (1999). Regulation of cerebral metabolic rate. In *Basic neurochemistry: molecular, cellular and medical aspects*, G.J. Siegel, B.W. Agranoff, and R.W. Albers, eds. (Lippincott-Raven).
10. Cole, S.L., and Corday, E. (1956). Four-minute limit for cardiac resuscitation. *J. Am. Med. Assoc.* **161**, 1454–1458.
11. Adams, J.A. (2006). Endothelium and cardiopulmonary resuscitation. *Crit. Care Med.* **34**, S458–S465.
12. Bro-Jeppesen, J., Johansson, P.I., Hassager, C., Wanscher, M., Ostrowski, S.R., Bjerre, M., and Kjaergaard, J. (2016). Endothelial activation/injury and associations with severity of post-cardiac arrest syndrome and mortality after out-of-hospital cardiac arrest. *Resuscitation* **107**, 71–79.
13. Nakayama, S., Migliati, E., Amiry-Moghaddam, M., Ottersen, O.P., and Bhardwaj, A. (2016). Osmotherapy with hypertonic saline attenuates global cerebral edema following experimental cardiac arrest via perivascular pool of aquaporin-4. *Crit. Care Med.* **44**, e702–e710.
14. Wang, C.H., Huang, C.H., Tsai, M.S., Wang, C.C., Chang, W.T., Liu, S.H., and Chen, W.J. (2022). Inhaled Carbon Dioxide Improves Neurological Outcomes by Downregulating Hippocampal Autophagy and Apoptosis in an Asphyxia-Induced Cardiac Arrest and Resuscitation Rat Model. *J. Am. Heart Assoc.* **11**, e027685.
15. Pittman, R.N. (2011). In *Regulation of Tissue Oxygenation* (Morgan & Claypool Life Sciences).
16. Fischer, M., Böttiger, B.W., Popov-Cenic, S., and Hossmann, K.A. (1996). Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat. *Intensive Care Med.* **22**, 1214–1223.
17. Panchal, A.R., Bartos, J.A., Cabañas, J.G., Donnino, M.W., Drennan, I.R., Hirsch, K.G., Kudenchuk, P.J., Kurz, M.C., Lavonas, E.J., Morley, P.T., et al. (2020). Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care. *Circulation* **142**, S366–S468.
18. Nolan, J.P., Sandroni, C., Böttiger, B.W., Cariou, A., Cronberg, T., Friberg, H., Genbrugge, C., Hayward, K., Lilja, G., Moulart, V.R.M., et al. (2021). European Resuscitation Council and European Society of Intensive Care Medicine Guidelines 2021: Post-resuscitation care. *Resuscitation* **161**, 220–269.
19. Floyd, T.F., Clark, J.M., Gelfand, R., Detre, J.A., Ratcliffe, S., Guvakov, D., Lambertsen, C.J., and Ekenhoff, R.G. (2003). Independent cerebral vasoconstrictive effects of hyperoxia and accompanying arterial hypocapnia at 1 ATA. *J. Appl. Physiol.* **95**, 2453–2461.
20. Dell’Anna, A.M., Lamanna, I., Vincent, J.L., and Taccone, F.S. (2014). How much oxygen in adult cardiac arrest? *Crit. Care* **18**, 555.
21. Buunk, G., van der Hoeven, J.G., Frölich, M., and Frölich, M. (1996). Cerebral vasoconstriction in comatose patients resuscitated from a cardiac arrest? *Intensive Care Med.* **22**, 1191–1196.
22. Roberts, B.W., Kilgannon, J.H., Chansky, M.E., Mittal, N., Wooden, J., and Trzeciak, S. (2013). Association between postresuscitation partial pressure of arterial carbon dioxide and neurological outcome in patients with post-cardiac arrest syndrome. *Circulation* **127**, 2107–2113.
23. Yundt, K.D., and Dinger, M.N. (1997). The use of hyperventilation and its impact on cerebral ischemia in the treatment of traumatic brain injury. *Crit. Care Clin.* **13**, 163–184.
24. Wang, C.H., Chang, W.T., Tsai, M.S., Huang, C.H., and Chen, W.J. (2020). Synergistic Effects of Moderate Therapeutic Hypothermia and Levosimendan on Cardiac Function and Survival After Asphyxia-Induced Cardiac Arrest in Rats. *J. Am. Heart Assoc.* **9**, e016139.
25. Robba, C., Badenes, R., Battaglini, D., Ball, L., Sanfilippo, F., Brunetti, I., Jakobsen, J.C., Lilja, G., Friberg, H., Wendel-Garcia, P.D., et al. (2022). Oxygen targets and 6-month outcome after out of hospital cardiac arrest: a pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial. *Crit. Care* **26**, 323.
26. Wang, C.H., Chang, W.T., Huang, C.H., Tsai, M.S., Yu, P.H., Wang, A.Y., Chen, N.C., and Chen, W.J. (2014). The effect of hyperoxia on survival following adult cardiac arrest: a systematic review and meta-analysis of observational studies. *Resuscitation* **85**, 1142–1148.
27. Vaahersalo, J., Bendel, S., Reinikainen, M., Kurola, J., Tiainen, M., Raj, R., Pettilä, V., Varpula, T., and Skrifvars, M.B.; FINNRESUSCI Study Group (2014). Arterial blood gas tensions after resuscitation from out-of-hospital cardiac arrest: associations with long-term neurologic outcome. *Crit. Care Med.* **42**, 1463–1470.
28. Elmer, J., Scutella, M., Pullalarevu, R., Wang, B., Vagharia, N., Trzeciak, S., Rosario-Rivera, B.L., Guyette, F.X., Rittenberger, J.C., and DeZfulian, C.; Pittsburgh Post-Cardiac Arrest Service PCAS (2015). The association between hyperoxia and patient outcomes after cardiac arrest: analysis of a high-resolution database. *Intensive Care Med.* **41**, 49–57.
29. Wang, C.H., Huang, C.H., Chang, W.T., Tsai, M.S., Lu, T.C., Yu, P.H., Wang, A.Y., Chen, N.C., and Chen, W.J. (2015). Association between early arterial blood gas tensions and neurological outcome in adult patients following in-hospital cardiac arrest. *Resuscitation* **89**, 1–7.
30. Janz, D.R., Hollenbeck, R.D., Pollock, J.S., McPherson, J.A., and Rice, T.W. (2012). Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest. *Crit. Care Med.* **40**, 3135–3139.
31. Ebner, F., Ullén, S., Åneman, A., Cronberg, T., Mattsson, N., Friberg, H., Hassager, C., Kjaergaard, J., Kuiper, M., Pelosi, P., et al. (2019). Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial. *Crit. Care* **23**, 30.
32. Roberts, B.W., Kilgannon, J.H., Hunter, B.R., Puskarich, M.A., Pierce, L., Donnino, M., Leary, M., Kline, J.A., Jones, A.E., Shapiro, N.I., et al. (2018). Association Between Early Hyperoxia Exposure After Resuscitation From Cardiac Arrest and Neurological Disability: Prospective Multicenter Protocol-Directed Cohort Study. *Circulation* **137**, 2114–2124.
33. Zhao, S., Qian, J., Wang, J., Gong, P., Yang, Z., Cahoon, J., Wu, X., Duggal, N., Lin, C., and Tang, W. (2015). Effects of oxygen concentrations on postresuscitation myocardial oxidative stress and myocardial function in a rat model of cardiopulmonary resuscitation. *Crit. Care Med.* **43**, e560–e566.
34. Hope Kilgannon, J., Hunter, B.R., Puskarich, M.A., Shea, L., Fuller, B.M., Jones, C., Donnino, M., Kline, J.A., Jones, A.E., Shapiro, N.I., et al. (2019). Partial pressure of arterial carbon dioxide after resuscitation from cardiac arrest and neurological outcome: A prospective multi-center protocol-directed cohort study. *Resuscitation* **135**, 212–220.
35. Eastwood, G.M., Schneider, A.G., Suzuki, S., Peck, L., Young, H., Tanaka, A., Mårtensson, J., Warrillow, S., McGuinness, S., Parke, R., et al. (2016). Targeted therapeutic mild hypercapnia after cardiac arrest: A phase II multi-centre randomised controlled trial (the CCC trial). *Resuscitation* **104**, 83–90.
36. Bernard, S.A., Bray, J.E., Smith, K., Stephenson, M., Finn, J., Grantham, H., Hein, C., Masters, S., Stub, D., Perkins, G.D., et al. (2022). Effect of Lower vs Higher Oxygen Saturation Targets on Survival to Hospital Discharge Among Patients Resuscitated After Out-of-Hospital Cardiac Arrest: The EXACT Randomized Clinical Trial. *JAMA* **328**, 1818–1826.
37. Asehnoune, K., Roquilly, A., and Cinotti, R. (2018). Respiratory Management in Patients with Severe Brain Injury. *Crit. Care* **22**, 76.
38. Schmidt, H., Kjaergaard, J., Hassager, C., Mølstrom, S., Grand, J., Borregaard, B., Roelsgaard Obling, L.E., Venø, S., Sarkisian, L., Mamaev, D., et al. (2022). Oxygen Targets in Comatose Survivors of Cardiac Arrest. *N. Engl. J. Med.* **387**, 1467–1476.
39. Böttiger, B.W., Krumnikl, J.J., Gass, P., Schmitz, B., Motsch, J., and Martin, E. (1997). The cerebral ‘no-reflow’ phenomenon after cardiac arrest in rats—influence of low-flow reperfusion. *Resuscitation* **34**, 79–87.
40. Ames, A., 3rd, Wright, R.L., Kowada, M., Thurston, J.M., and Majno, G. (1968). Cerebral ischemia. II. The no-reflow phenomenon. *Am. J. Pathol.* **52**, 437–453.
41. Floyd, T.F., Clark, J.M., Gelfand, R., Detre, J.A., Ratcliffe, S., Guvakov, D., Lambertsen, C.J., and Ekenhoff, R.G. (2003). Independent cerebral vasoconstrictive effects of hyperoxia and accompanying arterial hypocapnia at 1 ATA. *J. Appl. Physiol.* **95**, 2453–2461.
42. Kety, S.S., and Schmidt, C.F. (1948). THE EFFECTS OF ALTERED ARTERIAL TENSIONS OF CARBON DIOXIDE AND OXYGEN ON CEREBRAL BLOOD FLOW AND CEREBRAL OXYGEN CONSUMPTION OF NORMAL YOUNG MEN. *J. Clin. Invest.* **27**, 484–492.
43. Kontos, H.A., Raper, A.J., and Patterson, J.L. (1977). Analysis of vasoactivity of local pH, PCO<sub>2</sub> and bicarbonate on pial vessels. *Stroke Vasc. Interv. Neurol.* **8**, 358–360.
44. Oddo, M., and Bösel, J.; Participants in the International Multidisciplinary Consensus Conference on Multimodality Monitoring (2014). Monitoring of brain and systemic oxygenation in neurocritical care patients. *Neurocrit. Care* **21** (Suppl 2), S103–S120.
45. Dopperberg, E.M., Zauner, A., Watson, J.C., and Bullock, R. (1998). Determination of the

- ischemic threshold for brain oxygen tension. *Acta Neurochir. Suppl.* 71, 166–169.
46. Marina, N., Christie, I.N., Korsak, A., Doronin, M., Brazhe, A., Hosford, P.S., Wells, J.A., Sheikhabaehi, S., Humoud, I., Paton, J.F.R., et al. (2020). Astrocytes monitor cerebral perfusion and control systemic circulation to maintain brain blood flow. *Nat. Commun.* 11, 131.
  47. Sekhon, M.S., Gooderham, P., Menon, D.K., Brasher, P.M.A., Foster, D., Cardim, D., Czosnyka, M., Smielewski, P., Gupta, A.K., Ainslie, P.N., and Griesdale, D.E.G. (2019). The Burden of Brain Hypoxia and Optimal Mean Arterial Pressure in Patients With Hypoxic Ischemic Brain Injury After Cardiac Arrest. *Crit. Care Med.* 47, 960–969.
  48. Le Roux, P., Menon, D.K., Citerio, G., Vespa, P., Bader, M.K., Brophy, G.M., Diring, M.N., Stocchetti, N., Videtta, W., Armonda, R., et al. (2014). Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: a statement for healthcare professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine. *Intensive Care Med.* 40, 1189–1209.
  49. Hifumi, T., Kawakita, K., Yoda, T., Okazaki, T., and Kuroda, Y. (2017). Association of brain metabolites with blood lactate and glucose levels with respect to neurological outcomes after out-of-hospital cardiac arrest: A preliminary microdialysis study. *Resuscitation* 110, 26–31.
  50. Lipinski, C.A., Hicks, S.D., and Callaway, C.W. (1999). Normoxic ventilation during resuscitation and outcome from asphyxial cardiac arrest in rats. *Resuscitation* 42, 221–229.
  51. Chen, B., Chen, G., Dai, C., Wang, P., Zhang, L., Huang, Y., and Li, Y. (2018). Comparison of quantitative characteristics of early post-resuscitation EEG between asphyxial and ventricular fibrillation cardiac arrest in rats. *Neurocrit. Care* 28, 247–256.
  52. Pilcher, J., Weatherall, M., Shirtcliffe, P., Bellomo, R., Young, P., and Beasley, R. (2012). The effect of hyperoxia following cardiac arrest - A systematic review and meta-analysis of animal trials. *Resuscitation* 83, 417–422.
  53. Kuisma, M., Boyd, J., Voipio, V., Alaspää, A., Roine, R.O., and Rosenberg, P. (2006). Comparison of 30 and the 100% inspired oxygen concentrations during early post-resuscitation period: a randomised controlled pilot study. *Resuscitation* 69, 199–206.
  54. Angelos, M.G., Kutala, V.K., Torres, C.A., He, G., Stoner, J.D., Mohammad, M., and Kuppusamy, P. (2006). Hypoxic reperfusion of the ischemic heart and oxygen radical generation. *Am. J. Physiol. Heart Circ. Physiol.* 290, H341–H347.
  55. Holmberg, M.J., Nicholson, T., Nolan, J.P., Schexnayder, S., Reynolds, J., Nation, K., Welsford, M., Morley, P., Soar, J., and Berg, K.M.; Adult Pediatric Advanced Life Support Task Forces at the International Liaison Committee on Resuscitation ILCOR (2020). Oxygenation and ventilation targets after cardiac arrest: A systematic review and meta-analysis. *Resuscitation* 152, 107–115.
  56. Jakkula, P., Reinikainen, M., Hästbacka, J., Loisa, P., Tiainen, M., Pettilä, V., Toppila, J., Lähde, M., Bäcklund, M., Okkonen, M., et al. (2018). Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. *Intensive Care Med.* 44, 2112–2121.
  57. Wang, C.H., Chang, W.T., Su, K.I., Huang, C.H., Tsai, M.S., Chou, E., Lu, T.C., Chen, W.J., Lee, C.C., and Chen, S.C. (2020). Neuroprognostic accuracy of blood biomarkers for post-cardiac arrest patients: A systematic review and meta-analysis. *Resuscitation* 148, 108–117.
  58. Wang, C.H., Chang, W.T., Huang, C.H., Tsai, M.S., Yu, P.H., Wu, Y.W., and Chen, W.J. (2020). Associations between early intra-arrest blood acidemia and outcomes of adult in-hospital cardiac arrest: A retrospective cohort study. *Journal of the Formosan Medical Association = Taiwan yi zhi.* 119, 644–651.
  59. McGuigan, P.J., Shankar-Hari, M., Harrison, D.A., Laffey, J.G., and McAuley, D.F. (2020). The interaction between arterial oxygenation and carbon dioxide and hospital mortality following out of hospital cardiac arrest: a cohort study. *Crit. Care* 24, 336.
  60. Miao, Y., Edelheit, A., Velmurugan, S., Borovnik-Lesjak, V., Radhakrishnan, J., and Gazmuri, R.J. (2015). Estrogen fails to facilitate resuscitation from ventricular fibrillation in male rats. *Am. J. Transl. Res.* 7, 522–534.
  61. Callaway, C.W., and Logue, E.S. (2008). Chapter 8 Asphyxial Cardiac Arrest. In *Animal Models of Acute Neurological Injury*, Jun Chen, Z.C. Xu and M. Xiao, eds. (Springer).
  62. Lamoureux, L., Radhakrishnan, J., and Gazmuri, R.J. (2015). A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique. *J. Vis. Exp.* 1, 52413.
  63. Wang, C.H., Huang, C.H., Chang, W.T., Tsai, M.S., Yu, P.H., Wu, Y.W., Hung, K.Y., and Chen, W.J. (2015). Monitoring of serum lactate level during cardiopulmonary resuscitation in adult in-hospital cardiac arrest. *Crit. Care* 19, 344.
  64. Council, N.R. (2011). *Guide for the Care and Use of Laboratory Animals*, Eighth Edition (The National Academies Press).
  65. Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., Clark, A., Cuthill, I.C., Dirnagl, U., et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. *PLoS Biol.* 18, e3000410.
  66. Nishijima, T., Okamoto, M., Matsui, T., Kita, I., and Soya, H. (2012). Hippocampal functional hyperemia mediated by NMDA receptor/NO signaling in rats during mild exercise. *J. Appl. Physiol.* 112, 197–203.
  67. Yu, S., Wu, C., Zhu, Y., Diao, M., and Hu, W. (2022). Rat model of asphyxia-induced cardiac arrest and resuscitation. *Front. Neurosci.* 16, 1087725.
  68. Oghifobibi, O.A., Toader, A.E., Nicholas, M.A., Nelson, B.P., Alindogan, N.G., Wolf, M.S., Kline, A.E., Nouraie, S.M., Bondi, C.O., Iordanova, B., et al. (2022). Resuscitation with epinephrine worsens cerebral capillary no-reflow after experimental pediatric cardiac arrest: An in vivo multiphoton microscopy evaluation. *J. Cereb. Blood Flow Metab.* 42, 2255–2269.
  69. Abella, B.S., Zhao, D., Alvarado, J., Hamann, K., Vanden Hoek, T.L., and Becker, L.B. (2004). Intra-arrest cooling improves outcomes in a murine cardiac arrest model. *Circulation* 109, 2786–2791.
  70. Leary, S. (2013). AVMA Guidelines for the Euthanasia of Animals: 2013 Edition (American Veterinary Medical Association). <https://www.avma.org/KB/Policies/Documents/euthanasia.pdf>.
  71. Dolenc, P., Pilipović, K., Rajič, J., and Župan, G. (2015). Temporal pattern of neurodegeneration, programmed cell death, and neuroplastic responses in the thalamus after lateral fluid percussion brain injury in the rat. *J. Neuropathol. Exp. Neurol.* 74, 512–526.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Caspase-3 (D3R6Y) Rabbit mAb	Cell Signaling Technology	#14220; RRID:AB_2798429
PARP Antibody	Cell Signaling Technology	#9542; RRID:AB_2160739
Rat NSE(Neuron Specific Enolase) ELISA Kit	Elabsience Biotechnology	Cat.No.:E-EL-R0058
Rat S100B(S100 Calcium Binding Protein B) ELISA Kit	Elabsience Biotechnology	Cat.No.:E-EL-R0868
Rat Cardiac Troponin I ELISA Kit	Abcam	#ab246529
TBARS Assay Kit	Cayman Chemical	Item No. 10009055
DeadEnd™ Fluorometric TUNEL System	Promega	G3250
<b>Software and algorithms</b>		
ImageJ	National Institutes of Health	<a href="https://ImageJ.net/ij/index.html">https://ImageJ.net/ij/index.html</a>
<b>Other</b>		
FLUORO-JADE® C	EMD Millipore Corporation	Product Catalog Number:AG325-30MG, Lot # 3126966

### RESOURCE AVAILABILITY

#### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Wen-Jone Chen ([wjchen1955@ntu.edu.tw](mailto:wjchen1955@ntu.edu.tw)).

#### Materials availability

This study did not generate new unique reagents.

#### Data and code availability

- All data reported in this paper will be shared by the [lead contact](#) upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the [lead contact](#) upon request.

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### Animals

This research was approved by the Institutional Animal Care and Use Committee of the College of Medicine, National Taiwan University (reference number: 20180314) and performed following the Guide for the Care and Use of Laboratory Animals.<sup>64</sup> The analysis and results were conducted and reported according to Animal Research Reporting of *In Vivo* Experiments guidelines.<sup>65</sup> Animals were housed in a temperature-controlled environment (22°C) under a 12:12 h dark/light cycle and had free access to food and water.

#### Surgical preparation

An established asphyxia-induced CA rat model<sup>8,14,24</sup> was adopted in this study. Fourteen-week-old male Wistar rats, weighing approximately 450–500 gm, were employed for experiments. Before surgery, all animals were fasted for 12 h with free access to water. The animals were anesthetized using intraperitoneal pentobarbital (45 mg/kg). Then, tracheal intubation was performed with the insertion of a 14G venous catheter (Angiocath, Becton Dickinson, NJ, USA), including the following steps: (1) employ forceps to extract the tongue and introduce a laryngoscope blade into the oral cavity for observing the vocal cords; (2) introduce the venous catheter (with the needle replaced by a blunt stylet) through the vocal cords; (3) connect the catheter to the ventilator circuit and fasten it under the chin using a suture. Mechanical ventilation (R407, RWD Life Science, Hofheim, Germany) was initiated at a tidal volume of 0.6 mL/100 g body weight, a frequency of 100 breaths/min, positive end-expiratory pressure of 5 cmH<sub>2</sub>O, and an iO<sub>2</sub> concentration of 21%. CBF and PbtO<sub>2</sub> levels were continuously monitored using OxyFlo Pro and OxyLite Pro (Oxford-Optronix, Oxford, UK) instruments, respectively, via a fiber sensor (NX-BF/OFT/E, Oxford-Optronix) inserted through a small cranial window over the left hemisphere. The insertion site was marked on the dura with the stereotaxic coordinate anteroposterior (−3.5 mm) and lateral (2.0 mm) from the bregma. The rats were then fixed to a customized stereotaxic

frame in the supine position. The fiber sensor was inserted 2 mm from the dura into the dorsal hippocampal CA1 region.<sup>66</sup> The right femoral artery and left jugular vein were cannulated to obtain arterial blood pressure and blood samples and administer medications, respectively. Electrocardiographic leads (SP844, MEMSCAP, Skoppum, Norway) were connected to a data acquisition system (Labchart 8 software, AD Instruments, Sydney, Australia) via their corresponding transducers and signal conditioners. Rectal temperature was maintained at 36.5°C–37.5°C by a homeothermic control pad (RightTemp, Kent Scientific, Torrington, CT, USA).

### Asphyxia-induced CA and CPR

Figure 1 shows the experimental protocol. CA was induced by clamping the endotracheal tube and defined as mean arterial pressure (MAP)  $\leq$  20 mmHg. Neuromuscular blockers were not administered before asphyxia. Asphyxia-induced CA experiments could proceed with or without neuromuscular blockers.<sup>67</sup> In our experiments, the rats were fixed to a customized stereotaxic frame in the supine position. Because of the tight fixation to the frame, neuromuscular blockers were not needed to avoid equipment disconnection.<sup>61,67</sup> CPR was started 7 min after asphyxia, with one intravenous epinephrine (0.002 mg/100 g) dose, one sodium bicarbonate (1 mEq/kg) dose, and chest compressions. Chest compressions were performed manually by using two fingers to tap on the center of the sternum forcefully and sharply. The investigator's remaining hand would hold and stabilize the rib cage, ensuring proper chest recoil. The chest compression frequency was 200 beats/min, and the depth was approximately 1/3 the anteroposterior thorax diameter. No audiovisual feedback was used during CPR. Instead, the quality of chest compression was recognized by observing the pressure waves in the arterial catheter, as suggested by previous studies.<sup>61</sup> Manual chest compression was adjusted to maintain MAP  $>$ 40 mmHg to ensure high-quality CPR. During CPR, uninterrupted chest compressions led to a gradual rise in MAP within 30–60 s. Typically, signs of spontaneous cardiac activity emerged as MAP approached the 40 to 50 mmHg range, which usually took about 45–75 s of CPR. Chest compressions would persist until spontaneous arterial pressure waves were seen and an electrocardiographic signal was detected. During CPR, ventilatory  $iO_2$  concentration was 100%. ROSC was defined as MAP  $\geq$  40 mmHg for 10 min. Rats were randomly allocated to four study groups 15 min after ROSC. A computer-generated random number list with a block size of four was generated for the randomization. Randomized animals were ventilated with the following different combinations of  $iO_2$  and  $iCO_2$  concentrations for 150 min: 88%  $O_2$ +12%  $N_2$  (88%  $iO_2$  group), 50%  $O_2$ +50%  $N_2$  (50%  $iO_2$  group), 88%  $O_2$ +12%  $CO_2$  (88%  $iO_2$ +12%  $iCO_2$  group), and 50%  $O_2$ +12%  $CO_2$ +38%  $N_2$  (50%  $iO_2$ +12%  $iCO_2$  group). Previous studies<sup>68</sup> have shown that epinephrine administration during CPR produced microvascular alterations during the first-hour post-ROSC, including vasoconstriction, capillary stasis, and prolonged cortical transit time, which may confound our observations of the effects of  $iO_2$  and  $iCO_2$  on CBF and Pbt $O_2$ . Therefore, epinephrine infusion was not used after ROSC. During the intervention, anesthesia depth was monitored by observing the heart rate, MAP, and response to painful stimuli (pedal withdrawal reflex). If required, additional doses of pentobarbital (10 mg/kg) were administered intravenously every 30 min to maintain a surgical plane of anesthesia. In contrast, neuromuscular blocking agents were not administered during the post-ROSC period to prevent equipment disconnection because of the tight fixation to the frame. Also, gasping was not observed during the intervention period because of the respiratory depression caused by the pentobarbital. Therefore, there may be no gasping-related effects on lung functions and haemodynamics.

### Outcome measures of survival and neurological recovery

After a 150 min intervention, the rats were returned to their cages after the wounds closed. At 24 h post-ROSC, rat survival status was recorded; neurological outcomes were assessed using rat NFS (Table S1)<sup>69</sup> by researchers blinded to the treatment allocations. Rats were then humanely euthanized using intraperitoneal pentobarbital (45 mg/kg), followed by exsanguination.<sup>70</sup> After sacrifice, blood samples were collected from the right atrium; the right hippocampus was separated, cryofixed in liquid nitrogen, and stored at  $-80^\circ\text{C}$ ; the left harvested hippocampus was fixed in 4% formaldehyde in 0.1 M phosphate buffer.

## METHOD DETAILS

### Enzyme-linked immunosorbent assay (ELISA)

ELISA kits of NSE (#E-EL-R0058; Elabscience Biotechnology, Houston, TX), S100 $\beta$  (#E-EL-R0868; Elabscience Biotechnology), and cardiac troponin I (#ab246529; Abcam, Cambridge, UK) were used to determine their plasma levels in association with brain and heart injuries based on manufacturers instructions.

### Thiobarbituric acid reactive substance (TBARS) assay

The specimens of the right hippocampus were homogenized in RIPA buffer with protease and phosphatase inhibitors (#78441; Thermo Fisher Scientific, Waltham, MA). After centrifugation, the resulting supernatant was analyzed with the TBARS assay kit (#10009055; Cayman Chemical, Ann Arbor, MI) to measure the concentration of MDA, a lipid peroxidation product.

### TUNEL assay

To evaluate apoptosis, the specimens of the left hippocampus were assayed using the DeadEnd Fluorometric TUNEL System (G3250, Promega, Madison, WI) according to the manufacturer's instructions. TUNEL was performed on 4- $\mu\text{m}$ -thick paraffin-embedded coronal sections. The cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). The apoptotic cells were examined by fluorescence microscopy (EVOS FL Auto Imaging System, Thermo Fisher Scientific, Waltham, MA, USA). For quantitative comparisons, viewing fields were randomly selected



in hippocampal CA1 and CA3 regions for each sample.<sup>71</sup> Each field was photographed under microscopy at a 510/42 nm wavelength (green TUNEL) and a 447/60 nm wavelength (bluish-violet DAPI). PhotoImpact X3 (Corel, Ottawa, Canada) was used to merge the two images for the final counting analysis with ImageJ software (Version 1.52a, National Institutes of Health, Bethesda, MD, USA). TUNEL-positive cell densities (count/mm<sup>2</sup>) in the regions mentioned above were measured at 50× magnification, with an area of each microscopic field of approximately 0.48 mm<sup>2</sup>.

### FJC staining

To assess degenerating neurons, the specimens of the left hippocampus were stained with FJC (#AG325-30MG; EMD Millipore Corporation, Temecula, CA) per the manufacturer's instructions. Nuclei were stained with DAPI. The method of quantifying FJC-positive cells was the same as that using the TUNEL assay described above.

### WB analysis

The specimens of the right hippocampus were used for WB. The primary antibodies used were for caspase-3 (#14220; Cell Signaling Technology, Danvers, MA) and PARP (#9542; Cell Signaling Technology), while b-actin (HRP-60008; Proteintech Group, Rosemont, IL) was used as a loading control.

## QUANTIFICATION AND STATISTICAL ANALYSIS

The primary outcome of this study was NFS, which was used for *a priori* sample size calculation. For between-group comparisons, 17 animals/group were shown to be required to demonstrate a mean difference of 1.5 in NFS, with a power of 80% at the 5% level and a standard deviation of 1.5 (MedCalc, version 20.114; MedCalc Software, Ostend, Belgium). If the 24 h survival rate was assumed to be 70%,<sup>8,24</sup> the required size of each group was calculated to be 24 to compensate for losses. CBF was expressed as the proportion of the baseline (%baseline), and  $\Delta$ PbtO<sub>2</sub> was computed based on PbtO<sub>2</sub> at a particular time point minus the baseline.<sup>46</sup> Categorical data were expressed as count and proportion and compared using the chi-squared test. Continuous data were expressed as the median and interquartile range (IQR) and compared using the Kruskal-Wallis test. *Post hoc* Dunn's test was used for pairwise comparisons between each experimental group. Time-based measurements were compared using two-way repeated-measures ANOVA. Survival curves were created by the Kaplan-Meier method and compared by the log rank test. In sensitivity analysis, two-way ANOVA was used to examine the interaction between iO<sub>2</sub> and iCO<sub>2</sub> for NFS, and Tukey's test was used for *post hoc* pairwise comparisons. A two-tailed  $p < 0.05$  was considered statistically significant. All statistical tests were performed in GraphPad Prism Version 9.5.0 (GraphPad Software, La Jolla, CA).

## ADDITIONAL RESOURCES

None.